Pfizer profits jump on strong sales of COVID-19 products
NewwYork,wUSw-w PfizerKreported aKjumpKinKsecondYquarterKprofY itsKbehindKaKnearKdoublingKof revenuesKdrivenKbyKsalesKofKits vOVIwYdlKvaccineKandKtheraY peuticKdrugKPaxlovida
TheKdrugmakerKraisedKsome ofKitsKoverallKfinancialKbenchY marksWKbutKmaintainedKecee salesKtargetsKforKitsKtwoKvovidY dlKproductsmKUSOfebnKfromKthe vaccineKcoYdevelopedKwithKzerY manKcompanyKuioNTechnKand USOeebnKfromKPaxlovida
TheKtotalKisKequalKtoKjustKover halfKofKforecastedKeceeKtotal revenuesa
InKtheKquarterKendingKJune fcWKprofitsKwereKUSOlalbnWKup jkKperKcentKfromKtheKyearYago periodKfollowingKaKgjKperKcent jumpKinKrevenuesKtoKUSOejajbna
USKofficialsKlastKmonthKapY provedKemergencyKauthorizaY tionKtoKPfizerKandKModernaKfor vOVIwYdlKvaccinesKinKunderY fiveYyearYoldsWKtheKfinalKage groupKawaitingKimmunizationKin mostKcountriesa
PfizerKisKcurrentlyKworkingKon aKvOVIwYdlKOmicronKvaccine boosterKcandidateKforKtheKfallW assumingKregulatoryKapprovalKis grantedWKcompanyKofficialsKsaida
PfizerKandKzermanKuioNTech haveKalsoKsubmittedKdataKforKan OmicronKvaccineKtoKtheKxuroY peanKMedicinesKtgencya
MPfizerKisKwellKpositionedKto satisfyKitsKcurrentKcontractual obligationsKandKpotentialKdeY mandKwithinKitsKproductionKcaY pacityKthroughKtheKendKofKthe yearWMKsaidKchiefKexecutiveKtlY bertKuourlaKinKaKstatementa
SalesKforKbothKitsKvovidYdl productsKroseKduringKtheKquarY tera
RevenuesKforKtheKvaccine cameKinKatKUSOkakbnWKupKdfKper centKfromKtheKyearYagoKperiodW whileKsalesKofKPaxlovidKwere USOkadbnK–KaKbigKjumpKoverKthe priorKquarterKfollowingKaKfiveY foldKgrowthKinKUSKutilizationa